Angioimmunoblastic T-cell lymphoma (AITL) is a life-threatening hematological malignancy. For patients with poor prognosis, especially those with expected survival less than 1 year, the benefits from traditional regimens are extremely limited. Theref...
Presently, pathologists need to stain biopsy samples with standard and antibody-based immunocytochemistry (ICC) reagents for final diagnosis. Antibody reagents take hours to days to perform staining, along with requiring specialized equipment and tec...
There is no standard of care in relapsed/refractory T-cell/natural killer-cell lymphomas. Patients often cycle through cytotoxic chemotherapy (CC), epigenetic modifiers (EM) or small molecule inhibitors (SMI) empirically. Ideal therapy at each line r...
Journal of imaging informatics in medicine
Feb 6, 2024
This study aimed to examine the feasibility of utilizing radiomics models derived from F-FDG PET/CT imaging to screen for T-cell lymphoma in children with lymphoma. All patients had undergone F-FDG PET/CT scans. Lesions were extracted from PET/CT and...
UNLABELLED: T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies...
Lymphoma, a clonal malignancy from lymphocytes, includes diverse subtypes requiring distinct immunohistochemical stains for accurate diagnosis. Limited biopsy specimens often restrict the use of multiple stains, complicating diagnostic workflows. Lym...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.